Akèy › Kansè Poumon ki pa ti selil › Virginia › Arlington
Etid klinik pou Kansè Poumon ki pa ti selil nan Arlington, VA
104 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Arlington (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Virginia Cancer Specialists - Fairfax /ID# 272004, Fairfax · 11 mi lwen
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- Kaiser Permanente Tysons Corner Medical Center, McLean · 5 mi lwen
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Inova Schar Cancer Institute, Fairfax · 11 mi lwen
- NEXT Virginia, Fairfax · 11 mi lwen
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Ap rekriteFaz 3
- Virginia Cancer Specialists ( Site 0167), Fairfax · 11 mi lwen
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
Ap rekriteFaz 2/3
- Virginia Cancer Specialists, PC, Fairfax · 11 mi lwen
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
Ap rekriteFaz 3
- Virginia Cancer Specialists ( Site 0114), Fairfax · 11 mi lwen
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
Ap rekriteFaz 1
- Site 04, Fairfax · 11 mi lwen
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Ap rekriteFaz 2
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
Ap rekriteFaz 1
- ALX Center 2, Fairfax · 11 mi lwen
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Ap rekriteFaz 3
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
A Study of PHN-012 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1
- PHN-012-001 Site, Fairfax · 11 mi lwen
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Ap rekriteFaz 3
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Ap rekriteFaz 2
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
Ap rekriteFaz 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 1
- Virginia Cancer Specialists PC, Fairfax · 11 mi lwen
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Ap rekriteFaz 2
- Research Site, Fairfax · 11 mi lwen
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Ap rekriteFaz 2/3
- Virginia Cancer Specialists - Arlington, Arlington
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Ap rekriteFaz 1/2
- Inova Schar Cancer Institute Clinical Trials, Fairfax · 11 mi lwen
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- NEXT Oncology Virginia, Fairfax · 11 mi lwen
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Ap rekriteFaz 1
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Ap rekriteFaz 1/2
- Next Oncology Virginia Cancer Specialist, Fairfax · 11 mi lwen
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 3
- Research Site, Fairfax · 11 mi lwen
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Ap rekriteFaz 3
- Clinical Study Site, Fairfax · 11 mi lwen
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
Ap rekriteFaz 3
- Virginia Cancer Specialists, Arlington
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Ap rekriteFaz 3
- Virginia Cancer Specialists, PC, Fairfax · 11 mi lwen
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Ap rekriteFaz 1
- NEXT - Virginia, Fairfax · 11 mi lwen
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Ap rekriteFaz 1/2
- NEXT Virginia, Fairfax · 11 mi lwen
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Ap rekriteFaz 2/3
- Local Institution - 007-814-D, Arlington
- USOR - Virginia Cancer Specialists - Fairfax Office, Fairfax · 11 mi lwen
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
Ap rekriteFaz 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Ap rekriteFaz 1/2
- Inova Schar Cancer Institute, Fairfax · 11 mi lwen
- Next Oncology Virginia, Fairfax · 11 mi lwen
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Virginia Cancer Specialists (Fairfax) - USOR, Fairfax · 11 mi lwen
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Ap rekriteFaz 1
- NEXT Oncology - Virginia Cancer Specialists, Fairfax · 11 mi lwen
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- USO-Virginia Cancer Specialists, PC, Fairfax · 11 mi lwen
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Ap rekriteFaz 3
- USO - Virginia Cancer Specialists, Fairfax · 11 mi lwen
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Ap rekriteFaz 1
- NEXT Oncology Virginia, Fairfax · 11 mi lwen
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Ap rekriteFaz 3
- Research Site, Fairfax · 11 mi lwen
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Ap rekriteFaz 1
- NEXT Oncology, Fairfax · 11 mi lwen
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
Ap rekriteFaz 1/2
- NEXT Virginia, Fairfax · 11 mi lwen
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Ap rekriteFaz 1/2
- NEXT Virginia, Fairfax · 11 mi lwen
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Ap rekriteFaz 1
- Virginia Cancer Specialists, PC, Fairfax · 11 mi lwen
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Ap rekriteFaz 1
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Ap rekriteFaz 3
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- NEXT Virginia, Fairfax · 11 mi lwen
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Research Site, Fairfax · 11 mi lwen
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Ap rekriteFaz 2
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Ap rekriteFaz 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Ap rekriteFaz 1
- Inova Schar Cancer Institute, Falls Church · 4 mi lwen
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Research Site, Fairfax · 11 mi lwen
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Ap rekriteFaz 3
- Inova Schar Cancer Institute, Fairfax · 11 mi lwen
- Inova Fair Oaks Hospital, Fairfax · 11 mi lwen
A Study of DM005 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- NEXT Oncology Virginia, Fairfax · 11 mi lwen
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Clinical Trial Site, Fairfax · 11 mi lwen
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 1/2
- NEXT Virginia, Fairfax · 11 mi lwen
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Ap rekriteFaz 1/2
- NEXT Virginia, Fairfax · 11 mi lwen
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- NEXT Oncology - Virginia Cancer Specialists, Fairfax · 11 mi lwen
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Ap rekriteFaz 1/2
- USOR Virginia Cancer Specialists, Fairfax · 11 mi lwen
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Ap rekriteFaz 1/2
- NEXT Virginia, Fairfax · 11 mi lwen
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Next Virginia, Fairfax · 11 mi lwen
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
Ap rekriteFaz 3
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Ap rekriteFaz 1
- NEXT Virginia, Fairfax · 11 mi lwen
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
Ap rekriteFaz 1
- NEXT Virginia, Fairfax · 11 mi lwen
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Ap rekriteFaz 1/2
- NEXT Virginia, Fairfax · 11 mi lwen
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
Ap rekriteFaz 1
- NEXT Virginia, Fairfax · 11 mi lwen
A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer
Ap rekriteFaz 1/2
- Research Site, Fairfax · 11 mi lwen
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Ap rekriteFaz 1
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
Ap rekriteFaz 1
- NEXT Virginia, Fairfax · 11 mi lwen
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Research Site, Fairfax · 11 mi lwen
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Ap rekriteFaz 1/2
- NEXT Oncology Virginia, Fairfax · 11 mi lwen
A Study of LY4175408 in Participants With Advanced Cancer
Ap rekriteFaz 1
- NEXT Virginia, Fairfax · 11 mi lwen
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Ap rekriteFaz 1
- Virginia Cancer Specialists - Fairfax /ID# 232592, Fairfax · 11 mi lwen
Study of XB010 in Subjects With Solid Tumors
Ap rekriteFaz 1
- Inova Schar Cancer, Fairfax · 11 mi lwen
- NEXT Virginia, Fairfax · 11 mi lwen
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Ap rekriteFaz 1
- NEXT Texas LLC - Virginia, Fairfax · 11 mi lwen
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- NEXT Virginia, Fairfax · 11 mi lwen
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Research Site, Fairfax · 11 mi lwen
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Ap rekriteFaz 1
- Research Site, Fairfax · 11 mi lwen
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Kaiser Permanente Tysons Corner Medical Center, McLean · 5 mi lwen
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Ap rekriteFaz 1
- NEXT Oncology Virginia, Fairfax · 11 mi lwen
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Ap rekriteFaz 1/2
- NEXT Virginia, Fairfax · 11 mi lwen
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Ap rekriteFaz 3
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Ap rekriteFaz 1/2
- NEXT Oncology, Fairfax · 11 mi lwen
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Ap rekriteFaz 1
- NEXT Oncology Virginia, Fairfax · 11 mi lwen
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Ap rekriteFaz 1/2
- Next Oncology Virginia, Fairfax · 11 mi lwen
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Research Site, Fairfax · 11 mi lwen
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2/3
- Kaiser Permanente Tysons Corner Medical Center, McLean · 5 mi lwen
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Kaiser Permanente Tysons Corner Medical Center, McLean · 5 mi lwen
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Ap rekriteFaz 2
- Inova Fairfax Hospital, Fairfax · 11 mi lwen
A 2-part Phase 1/2 Open-label Trial on ODM-212
Ap rekriteFaz 1/2
- NEXT Oncology Virginia, Fairfax · 11 mi lwen
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Ap rekriteFaz 1/2
- NEXT Virginia, Fairfax · 11 mi lwen
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Ap rekriteFaz 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
Ap rekriteFaz 1
- Research Site, Fairfax · 11 mi lwen
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Ap rekriteFaz 1/2
- NEXT Virginia, Fairfax · 11 mi lwen
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1/2
- NEXT Virginia, Fairfax · 11 mi lwen
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- NEXT Virginia, Fairfax · 11 mi lwen
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Ap rekriteFaz 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- NEXT Virginia, Fairfax · 11 mi lwen
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
Ap rekriteFaz 1/2
- NEXT, Virginia, Fairfax · 11 mi lwen
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Ap rekriteFaz 1
- Dren Investigational Site, Fairfax · 11 mi lwen
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Ap rekriteFaz 1
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
Ap rekriteFaz 1
- NEXT Oncology, Fairfax · 11 mi lwen
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Research Site 102, Fairfax · 11 mi lwen
- Research Site 112, Fairfax · 11 mi lwen
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
Ap rekriteFaz 2
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Ap rekriteFaz 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
Ap rekriteFaz 1/2
- NEXT Virginia, Fairfax · 11 mi lwen
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY121 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH57 etid
- Washington, DC55 etid
- Seattle, WA53 etid
Lòt etid nan Arlington
- Kansè Metastatik53 etid
- Kansè kolorektal52 etid
- Kansè (tout kalite)48 etid
- Kansè nan tete47 etid
- Kansè ovè46 etid
- Kansè poumon41 etid
- Kansè Endomèt39 etid
- Kansè pankreyas33 etid
- Karsinòm selil skuamèz tèt ak kou26 etid
- Kansè poumon selil ti23 etid
- Kansè lestomak20 etid
- Kansè tete negatif triple20 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.